Actinium Pharmaceuticals Inc (ATNM) Short Interest Update

Actinium Pharmaceuticals Inc (NYSEAMERICAN:ATNM) was the target of a significant decrease in short interest in the month of December. As of December 31st, there was short interest totalling 1,930,639 shares, a decrease of 11.1% from the December 14th total of 2,172,039 shares. Based on an average daily volume of 667,184 shares, the short-interest ratio is currently 2.9 days. Currently, 1.7% of the shares of the company are sold short.

A number of institutional investors have recently bought and sold shares of ATNM. Essex Investment Management Co. LLC acquired a new stake in Actinium Pharmaceuticals during the third quarter worth about $816,000. PNC Financial Services Group Inc. acquired a new stake in Actinium Pharmaceuticals during the third quarter worth about $617,000. Renaissance Technologies LLC grew its holdings in Actinium Pharmaceuticals by 1,269.5% during the second quarter. Renaissance Technologies LLC now owns 387,500 shares of the biotechnology company’s stock worth $248,000 after acquiring an additional 359,205 shares during the period. Vanguard Group Inc grew its holdings in Actinium Pharmaceuticals by 6.4% during the third quarter. Vanguard Group Inc now owns 2,575,754 shares of the biotechnology company’s stock worth $1,909,000 after acquiring an additional 154,403 shares during the period. Finally, Vanguard Group Inc. grew its holdings in Actinium Pharmaceuticals by 6.4% during the third quarter. Vanguard Group Inc. now owns 2,575,754 shares of the biotechnology company’s stock worth $1,909,000 after acquiring an additional 154,403 shares during the period.

A number of brokerages have recently weighed in on ATNM. Roth Capital set a $6.00 price objective on Actinium Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, October 10th. Zacks Investment Research lowered Actinium Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, December 3rd. Maxim Group set a $3.00 price objective on Actinium Pharmaceuticals and gave the company a “buy” rating in a report on Monday, December 3rd. Finally, Oppenheimer set a $5.00 price objective on Actinium Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, November 28th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Actinium Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $3.55.

Shares of ATNM stock opened at $0.44 on Friday. Actinium Pharmaceuticals has a fifty-two week low of $0.33 and a fifty-two week high of $0.87.

COPYRIGHT VIOLATION NOTICE: This report was first published by Community Financial News and is the property of of Community Financial News. If you are accessing this report on another site, it was illegally copied and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be read at https://www.com-unik.info/2019/01/12/actinium-pharmaceuticals-inc-atnm-short-interest-update.html.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted therapies for patients with cancers lacking effective treatment options. Its lead product candidate is Iomab-B that is in Phase III clinical studies for myeloablation and conditioning of the bone marrow prior to a bone marrow transplant for patients with relapsed or refractory acute myeloid leukemia (AML) age 55 and older.

See Also: Dow Jones Industrial Average (DJIA)

Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit